back to the overview


Press Release; Berlin, April 19, 2006


Major MOLOGEN shareholder increases investment


Absolute Capital Management crosses 10-percent threshold


MOLOGEN AG (ISIN DE0006637200) announces that the investment company Absolute Capital Management has increased its investment in MOLOGEN AG to more than 10 percent. Absolute Capital Management now holds 15.6 percent of MOLOGEN's shares. The investment company is headed by Florian Homm.

"MOLOGEN technologies stand for the long-term potential of investments in the markets of tumor-specific therapy and of combating infections," comments Florian Homm the share increase. "With further good progress in the development and subsequent marketing of the products resulting from these technologies, many people will benefit from the prevention and therapy of life-threatening diseases. To me, our share increase therefore is a long-term investment that is guided less by a focus on the current financial figures than by our expectance of future added value. We are convinced that the capital market underestimates the company's medium-term potential with its current company value of 80 million Euro. Thus, the American competitor Coley Pharmaceutical Group has a market value that is four times higher than MOLOGEN's," Homm explains.



MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.


Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


 back to the overview


Investor & Public Relations

  Joerg Petrass

Research & Development

  Dr. Matthias Schroff

Business Development

  Arlett Killat


To subscribe to our Newsletter please

 click here


To view our Reports

  click here